Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Apixaban Vs Vitamin K Antagonist As Anticoagulant Therapy in Patients with End-Stage Kidney Disease on Hemodialysis and with Atrial Fibrillation

Sofia Muzio, Gonzalo Artaza, Olga Benitez Hidalgo, Vicente Cortina, Desiree Campoy, Francisco Beas, Marc Bosch, Marina Serra, Francesc Bosch, Pável E Olivera

Blood (2023) 142 (Supplement 1): 4019.

https://doi.org/10.1182/blood-2023-190604

Published: 2023

Journal Articles

Management of Secondary Prevention in Venous Thromboembolism: Use of Reduced Doses of Rivaroxaban and Apixaban in Extended Therapy

Desiree Campoy, MD, Katia Flores, MD, Gonzalo Artaza, MD, César A Velasquez, MD, Tania Canals, MD, Erik A Johansson, MD, Agustí Peró, MD, Jorge Sierra, MD, Ramón Salinas, MD PhD, Pável E Olivera, MD

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-141908

Published: 2020

Journal Articles

Edoxaban Vs. Low Molecular Weight Heparin As Anticoagulant Therapy in Hospitalized Patients with Atrial Fibrillation and COVID-19 Infection

Pável E Olivera, MD, Desiree Campoy, MD, César A Velasquez, MD, Katia Flores, MD, Tania Canals, MD, Erik A Johansson, MD, Laia Martinez, MD, Jorge Sierra, MD, Juan Jose Cerezo, MD PhD, Ramón Salinas, MD PhD

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-143065

Published: 2020

Journal Articles

The Elevation of LIVER Enzymes in Patients with Atrial Fibrillation and COVID-19 Is a Marker of Bad Evolution and Mortality

Juan Jose Cerezo Manchado, MDPhD, Pável E Olivera, MD, María Dolores Lopez Abellan, Desiree Campoy Castaño, César A Velasquez, MD, Carlos Rodriguez Rojas, Veronica Ramos Arenas, Katia Flores, MD, Rubén Cárdenas Gámez, Luis García de Guadiana Romualdo, PhD, Teodoro Iturbe Hernandez, Jorge Sierra, MD, Ramón Salinas, MD PhD

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-142451

Published: 2020

Journal Articles

Effectiveness and Safety of Direct Oral Anticoagulants Vs. Low Molecular Weight Heparin As Anticoagulant Therapy in Patients with Active Cancer Therapy and Non Valvular Atrial Fibrillation

Pável E Olivera, MD, César A Velasquez, MD, Desirée Campoy, MD, Gonzalo Artaza, MD, Tania Canals, MD, Katia Flores, MD, Silvia Ruiz, MD, Alessandra Comai, MD, Erik A Johansson, MD, Gabriela S Ene, MD PhD, Gabriela Bastidas, MD, Maricel Subira, MD PhD, Jorge Sierra, MD, Ramón Salinas, MD PhD

Blood (2019) 134 (Supplement_1): 3661.

https://doi.org/10.1182/blood-2019-128300

Published: 2019

Journal Articles

Anticoagulation Challenges in Hematogeriatrics: Effectiveness and Safety of Direct Oral Anticoagulants Vs Vitamin k Antagonist in Elderly with Atrial Fibrillation

Desirée Campoy, MD, Gonzalo Artaza, MD, César A Velasquez, MD, Tania Canals, MD, Erik A Johansson, MD, Katia Flores, MD, Gabriela Bastidas, MD, Silvia Ruiz, MD, Gabriela S Ene, MD PhD, Alessandra Comai, MD, Maricel Subira, MD PhD, Ramón Salinas, MD PhD, Jorge Sierra, MD, Pável E Olivera, MD

Blood (2019) 134 (Supplement_1): 1162.

https://doi.org/10.1182/blood-2019-125150

Published: 2019

Journal Articles

Direct Oral Anticoagulant Vs Vitamin K Antagonist As Anticoagulant Therapy in Patients with Inherited and Acquired Thrombophilia

Pável E Olivera, MD, Desirée Campoy, MD, César A Velasquez, MD, Katia Flores, MD, Gabriela S Ene, MD PhD, Tania Canals, MD, Gonzalo Artaza, MD, Maricel Subira, MD, Sofía Vila, Undergraduate student, Jorge Sierra, MD, Ramón Salinas, MD PhD

Blood (2018) 132 (Supplement 1): 1254.

https://doi.org/10.1182/blood-2018-99-119114

Published: 2018

NARROW

Apixaban Vs Vitamin K Antagonist As Anticoagulant Therapy in Patients with End-Stage Kidney Disease on Hemodialysis and with Atrial Fibrillation

Management of Secondary Prevention in Venous Thromboembolism: Use of Reduced Doses of Rivaroxaban and Apixaban in Extended Therapy

Edoxaban Vs. Low Molecular Weight Heparin As Anticoagulant Therapy in Hospitalized Patients with Atrial Fibrillation and COVID-19 Infection

The Elevation of LIVER Enzymes in Patients with Atrial Fibrillation and COVID-19 Is a Marker of Bad Evolution and Mortality

Effectiveness and Safety of Direct Oral Anticoagulants Vs. Low Molecular Weight Heparin As Anticoagulant Therapy in Patients with Active Cancer Therapy and Non Valvular Atrial Fibrillation

Anticoagulation Challenges in Hematogeriatrics: Effectiveness and Safety of Direct Oral Anticoagulants Vs Vitamin k Antagonist in Elderly with Atrial Fibrillation

Direct Oral Anticoagulant Vs Vitamin K Antagonist As Anticoagulant Therapy in Patients with Inherited and Acquired Thrombophilia

Email alerts

ASH Publications

American Society of Hematology

Apixaban Vs Vitamin K Antagonist As Anticoagulant Therapy in Patients with End-Stage Kidney Disease on Hemodialysis and with Atrial Fibrillation

Management of Secondary Prevention in Venous Thromboembolism: Use of Reduced Doses of Rivaroxaban and Apixaban in Extended Therapy

Edoxaban Vs. Low Molecular Weight Heparin As Anticoagulant Therapy in Hospitalized Patients with Atrial Fibrillation and COVID-19 Infection

The Elevation of LIVER Enzymes in Patients with Atrial Fibrillation and COVID-19 Is a Marker of Bad Evolution and Mortality

Effectiveness and Safety of Direct Oral Anticoagulants Vs. Low Molecular Weight Heparin As Anticoagulant Therapy in Patients with Active Cancer Therapy and Non Valvular Atrial Fibrillation

Anticoagulation Challenges in Hematogeriatrics: Effectiveness and Safety of Direct Oral Anticoagulants Vs Vitamin k Antagonist in Elderly with Atrial Fibrillation

Direct Oral Anticoagulant Vs Vitamin K Antagonist As Anticoagulant Therapy in Patients with Inherited and Acquired Thrombophilia

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only